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1442. There is increasing evidence that the myocardial necrosis that occursduring coronary artery bypass grafting (CABG) surgery is due to, inpart, inadequate myocardial protection and that one of the underlyingmechanisms is related to activation of the sodium-hydrogen ex-changer (NHE). The NHE is one of 2 intracellular alkalinizingexchangers in mammalian cells; the second mechanism is the Na-
HCO3 exchanger. To date, 7 different isoforms of the NHE have been identified and
are termed NHE-1 through NHE-7. NHE-1 is the primary isoform in mammalian
myocardium. It is a 110-kd glycosylated protein localized in the sarcolemmal
membrane of the cardiomyocyte. Its activity is regulated, in part, by a proton sensor
on the cytosolic surface of the exchanger that is sensitive to intracellular H
concentration ([H]i). In the resting state the NHE-1 is relatively quiescent, but
during ischemia, increased intracellular accumulation of H stimulates the proton
sensor, and activity of the exchanger is, in turn, increased by allosteric modifications
of the molecule. The NHE-1 is also stimulated by other exogenous stimuli, such as
cytokines, endothelin 1 (ET-1), thrombin, -adrenergic agents, and byproducts of
ischemic metabolism, such as hydrogen peroxide and lysophosphatidylcholine.
NHE-1 activity has been implicated as a mechanism underlying both myocardial
and endothelial cell dysfunction caused by ischemia-reperfusion injury.1 During
ischemia, the associated increase in [H]i caused by anaerobic metabolism stimu-
lates the NHE-1, which leads to a concomitant increase in intracellular Na
concentration ([Na]i). Extrusion of Na ions is limited, however, by the inhibition
of the Na-K adenosine triphosphatase pump that occurs as a result of ischemia-
induced depletion of adenosine triphosphate. The increased [Na]i slows or reverses
the direction of the Na/Ca2 exchanger, which normally extrudes Ca2 in ex-
change for Na when operating in the forward direction. This reversal results in a
deleterious increase in intracellular Ca2, which is known as intracellular calcium
overload. This process is thought to be one of the key mechanisms underlying
ischemia-reperfusion injury in the heart, manifested as contractile dysfunction,
endothelial injury, necrosis, and apoptosis. It is important to note that it is not the
NHE-1 activation per se that directly results in myocyte injury and cell death but
rather its indirect effect associated with inhibition of Na-K adenosine triphos-
phatase and activity normally designed to prevent intracellular Na overload.
As a consequence of the deleterious physiologic effects of Ca2 overload
indirectly triggered by NHE-1 activity, a number of compounds have been devel-
oped to inhibit its activity, such as HOE 642 or cariporide. The long-term objective
is to use these compounds to treat patients at risk of ischemia-reperfusion injury (ie,
patients who undergo CABG surgery). Most experimental studies have demon-
strated that NHE-1 inhibition is associated with a reduction in postischemic arrhyth-
mias, necrosis, contractile dysfunction, and apoptosis. The preponderance of data
suggest that these beneficial effects are exerted when the agent is administered
before ischemia rather than afterward (ie, during reperfusion). There is evidence
suggesting that prolonged ischemia might reduce the activity of the exchanger, and
the exchanger could be stimulated at the time of reperfusion.2,3 However, results
have been variable when NHE-1 inhibitors have been administered at reperfusion.
Although cariporide was administered perioperatively in the GUARDIAN clinical
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trial, there are preclinical studies in which addition of
NHE-1 inhibitors to cardioplegia solutions was cardiopro-
tective.4 Castella´ and colleagues5 reported that a single 5
mg/kg intravenous pretreatment infusion of cariporide re-
versed postcardioplegia contractile dysfunction and reduced
markers of myocardial oxidant injury. They have also
shown that administration of cariporide as an adjunct to the
terminal reperfusate infusion of amino acid–enhanced car-
dioplegia at a dose of 40 mg/L (approximately 16 mg) was
cardioprotective.5
In this month’s issue of the Journal, the article by Cas-
tella´ and colleagues6 provides new insight into this conun-
drum of optimal timing of NHE-1 inhibition and suggests
that pretreatment with an NHE-1 inhibitor might be more
important in facilitating recovery from ischemia-reperfusion
injury than pH management of the cardioplegic reperfusate
advocated previously by this group. In this month’s report
the authors tested the hypothesis that pretreatment with the
NHE-1 inhibitor cariporide is more effective in attenuating
postcardioplegic myocardial injury independent of cardio-
plegia pH management strategy than buffering blood car-
dioplegia to pH 7.7 with tris hydroxymethyl aminomethane
(THAM) or maintaining an acidotic (pH 7.2) environment
by using this same blood cardioplegia without THAM. The
experiments were performed in a porcine model of 30
minutes of antecedent normothermic ischemia, followed by
30 minutes of cardioplegic arrest to create vulnerability to
postcardioplegia injury. Cariporide was administered as a
pretreatment before global ischemia in the 2 groups receiv-
ing either acidotic or alkalotic cardioplegia; in 2 other
groups acidotic or alkalotic cardioplegia was delivered
without pretreatment cariporide. Global left ventricular
function was assessed by means of pressure-volume analy-
sis, and myocardial damage was determined by measuring
creatine kinase-MB. Other blood biochemical measure-
ments included conjugated dienes as a measure of oxidant
generation and nitric oxide and ET-1 generation as an
indicator of endothelial function. The authors report that
that the combination of pretreatment cariporide and acidotic
or alkalotic cardioplegia was more cardioprotective than
either an extracellular acidotic or an alkalotic blood cardio-
plegia without cariporide pretreatment. They conclude that
pretreatment with an NHE-1 inhibitor can prevent myocar-
dial injury and that this protection is independent of pH
management of the cardioplegia solution. These are impor-
tant findings and suggest that NHE-1 inhibition represents a
novel approach to protecting the heart during surgical in-
tervention. The study adds to the growing body of evidence
that NHE-1 inhibitors are cardioprotective in both normal
and seriously injured myocardium when administered par-
enterally or as an adjunct to cardioplegia. The findings and
the experimental design of this study, however, raise several
important questions and interesting issues.
First, does exogenous pH management with buffers such
as THAM actually influence intracellular pH under the
experimental conditions imposed? THAM is known to
buffer intracellular pH. However, the acidic properties of
the nonbuffered cardioplegia in the absence of THAM could
have been conferred by the citrate-phosphate-dextrose
(CPD) solution used to chelate calcium, and whether this
was intracellular acidosis was not determined. The use of
CPD to chelate calcium is not specifically mentioned in the
article but can be inferred from historical formulations from
this group and from the extent of hypocalcemia (0.2 mEq/L)
of the solution. In addition, it is unclear whether the CPD-
induced hypocalcemia could have influenced the activity of
the Na/Ca2 exchanger and mitigated intracellular Ca2
accumulation independent of alterations in the pH of the
cardioplegia solutions.
Second, how important is the timing of intracellular pH
management in the absence or presence of cariporide pre-
treatment? According to the study design, cariporide was
administered before the onset of normothermic global isch-
emia, whereas the buffering interventions were exerted dur-
ing the added 30 minutes of “protected” ischemia with
intermittent delivery of cardioplegia. Therefore pretreat-
ment with an NHE-1 inhibitor presumably influenced the
intracellular milieu before any intracellular changes that
might have occurred as a result of modulation of pH in the
cardioplegic solution. Thus it is unclear whether the salutary
effects of cariporide were due to NHE-1 inhibition during
normothermic ischemia or to better myocardial protection
during cardioplegia. To answer these questions, intracellular
pH, Na, and Ca2 will need to be measured during nor-
mothermic ischemia, cardioplegic arrest, and subsequent
reperfusion. In addition, it is possible that cariporide had an
effect during reperfusion because of its relatively long half-
life.
Third, independent of the timing of action of cariporide
or pH modulation, what role if any did cariporide play in
directly inhibiting neutrophils or attenuating the triggers of
neutrophil activation and recruitment in postcardioplegic
myocardium in this preparation? These are relevant ques-
tions because ischemia, reperfusion, and cardiopulmonary
bypass stimulate the release of proinflammatory cytokines
that activate neutrophils, and NHE-1 inhibition blunts neu-
trophil activation through a pH-dependent mechanism. The
NHE-1 isoform is expressed in neutrophils,7 and its activa-
tion maintains an appropriately alkalotic state for optimal
reduced nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase activity and generation of superoxide
anions. Accordingly, inhibition of NHE-1 blocks respiratory
burst activity in activated neutrophils4 by maintaining the
intracellular H load created by the respiratory burst,
thereby inhibiting pH-sensitive NADPH oxidase activity.8
Some studies have shown, however, that higher concentra-
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tions of cariporide or other NHE inhibitors might be re-
quired to attenuate neutrophil respiratory burst activity than
that required to protect myocytes.4 In the absence of a direct
inhibitory effect on neutrophils, cariporide could have at-
tenuated the proinflammatory mediators that recruit neutro-
phils to activated endothelium, which is a critical step in the
initiation of the inflammatory cascade. Indeed, it is known
that the function of the coronary vascular endothelium is
blunted after nonsurgical and surgical ischemia-reperfusion.
The intracellular accumulation of Ca2 induced by NHE
activity9 mediates, in part, the increased expression of the
proinflammatory adhesion molecule ICAM-1 on coronary
vascular endothelium.10 This is consistent with reports by
other investigators that postischemic11 and postcardiople-
gic4 endothelial dysfunction is attenuated by NHE-1 inhib-
itors. However, it is not clear whether this is a direct
inhibition of neutrophil activation and neutrophil-mediated
injury or whether it is an attenuation of proinflammatory
mediators that trigger neutrophil activation.
The finding that ET-1 levels are lower after cariporide
treatment is an important one. ET-1 can be synthesized by
myocytes, as well as by vascular endothelium. Activation of
the ETA receptor by ET-1 released after ischemia and reper-
fusion causes myocyte injury, as well as vasoconstriction,
and ET-1 directly promotes calcium overload in myocytes
through activation of the ETA receptor subtype. This leads
to contractile dysfunction. ET-1 also causes endothelial
dysfunction by inhibiting the effects of nitric oxide. Finally,
increased levels of ET-1 stimulate activity of the NHE-1.
The observation by Castella´ and colleagues6 in this month’s
issue of the Journal that cariporide, but not buffered car-
dioplegia, reduced coronary sinus ET-1 levels not only
highlights a limitation of cardioplegia buffering strategies
but also suggests that a withdrawal of a longer-term sec-
ondary trigger of NHE-1 activity might be important in
favorably altering the pathogenesis of late reperfusion in-
jury and delayed deleterious postoperative events. This is
particularly relevant because there is increasing evidence in
patients that inadequate myocardial protection during car-
diac surgery for ischemic heart disease is associated with
decreased medium and long-term survival.
Finally, the majority of preclinical studies on the benefits
of NHE-1 inhibition have been performed in in vitro models
(cardiomyocytes and isolated perfused hearts) or in in vivo
preparations (regional or global acute ischemia) that do not
entirely simulate the complex conditions associated with
cardiac surgery by using cardiopulmonary bypass, intermit-
tent ischemia, and intraoperative cardioplegia delivery.
Also, many patients undergoing CABG surgery have sus-
tained an antecedent ischemic event. After initiating cardio-
pulmonary bypass, the heart is typically infused intermit-
tently with a cold cardioplegic solution or infused
continuously with tepid or warm cardioplegia. This delivery
of cardioplegia is a form of reperfusion, with potential
benefits and liabilities. On completion of the revasculariza-
tion operation, the crossclamp is removed, and the heart is
perfused globally through the grafts and the native diseased
vessels. It is at this time that the human heart is at additional
risk of myocardial injury caused by oxidant generation,
neutrophil-mediated or neutrophil-independent inflamma-
tory responses, or calcium overload. This complex clinical
scenario differs considerably from the relatively straightfor-
ward coronary occlusion-reperfusion protocols in which the
preponderance of studies has been conducted. If we are to
accept the challenge of extrapolating the cardioprotection
conferred by NHE-1 inhibitors reported in preclinical stud-
ies to the human situation, it is vital that we use animal
preparations that more closely mimic the human condition,
such as the model used by Castella´ and colleagues.6 Only in
this manner will we be able to more reliably use our pre-
clinical studies to evaluate new and more effective methods
of myocardial protection.
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